Marketing-authorisation holder
Glaxo Grp Ltd
14 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
14 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
14 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADVAIR DISKUS 100/500.1mg/inh; 0.05mg base/inh · Powder | Fluticasone, Salmeterol | United States | Marketed | 2000 |
| ADVAIR DISKUS 250/500.25mg/inh; 0.05mg base/inh · Powder | Fluticasone, Salmeterol | United States | Marketed | 2000 |
| ADVAIR DISKUS 500/500.5mg/inh; 0.05mg base/inh · Powder | Fluticasone, Salmeterol | United States | Marketed | 2000 |
| ADVAIR HFA0.045mg/inh; 0.021mg base/inh | 0.115mg/inh; 0.021mg base/inh | 0.23mg/inh; 0.021mg base/inh · Aerosol, metered | Fluticasone, Salmeterol | United States | Marketed | 2006 |
| BREO ELLIPTA0.05mg/inh; 0.025mg base/inh | 0.1mg/inh; 0.025mg base/inh | 0.2mg/inh; 0.025mg base/inh · Powder | Fluticasone, Vilanterol trifenatato | United States | Marketed | 2013 |
| FLOVENT DISKUS 1000.1mg/inh · Powder | Fluticasone | United States | Marketed | 2000 |
| FLOVENT DISKUS 2500.25mg/inh · Powder | Fluticasone | United States | Marketed | 2000 |
| FLOVENT DISKUS 500.05mg/inh · Powder | Fluticasone | United States | Marketed | 2000 |
| FLOVENT HFA0.044mg/inh | 0.11mg/inh | 0.22mg/inh · Aerosol, metered | Fluticasone | United States | Marketed | 2004 |
| ZANTAC15mg base/ml · Syrup | Ranitidine | United States | Not marketed | 1988 |
| ZANTAC 150150mg base · Tablet, effervescent | Ranitidine | United States | Not marketed | 1994 |
| ZANTAC 150150mg base/packet · Granule, effervescent | Ranitidine | United States | Not marketed | 1994 |
| ZANTAC 2525mg base · Tablet, effervescent | Ranitidine | United States | Not marketed | 1994 |
| ZANTAC 300300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Ranitidine | United States | Not marketed | 1983 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 14 | 14 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.